tradingkey.logo

Outset Medical Inc <OM.OQ> expected to post a loss of 41 cents a share - Earnings Preview

ReutersFeb 17, 2025 9:59 PM
  • Outset Medical Inc OM.OQ OM.O is expected to show a fall in quarterly revenue when it reports results on February 19 for the period ending December 31 2024

  • The San Jose California-based company is expected to report a 6.7% decrease in revenue to $28.474 million from $30.51 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Outset Medical Inc is for a loss of 41 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Outset Medical Inc is $3.00​, above​ its last closing price of $0.90. ​​​

The company's guidance on August 7 2024 for the period ended December 31 was for gross profit margin between 34% and 36%.

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.42

-0.42

-0.39

Beat

7.5

Jun. 30 2024

-0.45

-0.45

-0.47

Missed

-4.1

Mar. 31 2024

-0.56

-0.55

-0.57

Missed

-3.9​

Dec. 31 2023

-0.61

-0.61

-0.59

Beat

4.1

​​Sep. 30 2023

-0.67

-0.67

-0.71

Missed

-6.5

Jun. 30 2023

-0.84

-0.76

-0.90

Missed

-18​

Mar. 31 2023

-0.78

-0.74

-0.90

Missed

-21.3

Dec. 31 2022

-0.91

-0.86

-0.86

Met

0

This summary was machine generated February 17 at 21:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI